vs
Side-by-side financial comparison of Cytosorbents Corp (CTSO) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Cytosorbents Corp is the larger business by last-quarter revenue ($9.2M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). Cytosorbents Corp runs the higher net margin — -59.5% vs -60.3%, a 0.8% gap on every dollar of revenue. On growth, Cytosorbents Corp posted the faster year-over-year revenue change (0.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-4.9M). Over the past eight quarters, Cytosorbents Corp's revenue compounded faster (1.3% CAGR vs -6.7%).
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
CTSO vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $9.1M |
| Net Profit | $-5.5M | $-5.5M |
| Gross Margin | 73.7% | 49.4% |
| Operating Margin | -47.5% | -51.1% |
| Net Margin | -59.5% | -60.3% |
| Revenue YoY | 0.9% | -49.9% |
| Net Profit YoY | 27.4% | -184.8% |
| EPS (diluted) | $-0.09 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $9.1M | ||
| Q3 25 | $9.5M | $17.9M | ||
| Q2 25 | $9.6M | $15.7M | ||
| Q1 25 | $8.7M | $10.1M | ||
| Q4 24 | $9.2M | $18.2M | ||
| Q3 24 | $8.6M | $18.0M | ||
| Q2 24 | $8.8M | $13.5M | ||
| Q1 24 | $9.0M | — |
| Q4 25 | $-5.5M | $-5.5M | ||
| Q3 25 | $-3.2M | $2.4M | ||
| Q2 25 | $1.9M | $164.0K | ||
| Q1 25 | $-1.5M | $-3.6M | ||
| Q4 24 | $-7.6M | $6.5M | ||
| Q3 24 | $-2.8M | $3.2M | ||
| Q2 24 | $-4.3M | $-2.2M | ||
| Q1 24 | $-6.1M | — |
| Q4 25 | 73.7% | 49.4% | ||
| Q3 25 | 70.3% | 53.4% | ||
| Q2 25 | 70.9% | 62.5% | ||
| Q1 25 | 71.1% | 19.1% | ||
| Q4 24 | 68.4% | 78.7% | ||
| Q3 24 | 61.0% | 53.4% | ||
| Q2 24 | 73.5% | 29.8% | ||
| Q1 24 | 76.5% | — |
| Q4 25 | -47.5% | -51.1% | ||
| Q3 25 | -30.2% | 11.9% | ||
| Q2 25 | -37.6% | 7.5% | ||
| Q1 25 | -44.5% | -41.0% | ||
| Q4 24 | -37.1% | 39.6% | ||
| Q3 24 | -56.1% | 22.2% | ||
| Q2 24 | -40.4% | -18.0% | ||
| Q1 24 | -51.8% | — |
| Q4 25 | -59.5% | -60.3% | ||
| Q3 25 | -33.4% | 13.2% | ||
| Q2 25 | 20.2% | 1.0% | ||
| Q1 25 | -16.9% | -35.8% | ||
| Q4 24 | -82.7% | 35.6% | ||
| Q3 24 | -32.1% | 18.0% | ||
| Q2 24 | -48.6% | -16.4% | ||
| Q1 24 | -67.7% | — |
| Q4 25 | $-0.09 | $-0.06 | ||
| Q3 25 | $-0.05 | $0.03 | ||
| Q2 25 | $0.03 | $0.00 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $-0.14 | $0.10 | ||
| Q3 24 | $-0.05 | $0.03 | ||
| Q2 24 | $-0.08 | $-0.03 | ||
| Q1 24 | $-0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.2M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | $48.2M |
| Total Assets | $44.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.2M | $14.7M | ||
| Q3 25 | $7.5M | $13.6M | ||
| Q2 25 | $10.2M | $17.9M | ||
| Q1 25 | $11.6M | $19.5M | ||
| Q4 24 | $3.3M | $19.8M | ||
| Q3 24 | $5.7M | $27.4M | ||
| Q2 24 | $8.5M | $23.4M | ||
| Q1 24 | $8.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $4.4M | — |
| Q4 25 | $5.9M | $48.2M | ||
| Q3 25 | $9.0M | $52.9M | ||
| Q2 25 | $11.6M | $49.9M | ||
| Q1 25 | $14.5M | $45.2M | ||
| Q4 24 | $11.1M | $43.2M | ||
| Q3 24 | $13.4M | $32.4M | ||
| Q2 24 | $17.4M | $28.6M | ||
| Q1 24 | $19.6M | — |
| Q4 25 | $44.2M | $82.3M | ||
| Q3 25 | $45.8M | $82.3M | ||
| Q2 25 | $48.0M | $78.5M | ||
| Q1 25 | $50.8M | $73.9M | ||
| Q4 24 | $47.4M | $73.4M | ||
| Q3 24 | $47.8M | $61.6M | ||
| Q2 24 | $53.4M | $91.5M | ||
| Q1 24 | $47.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.23× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $2.0M |
| Free Cash FlowOCF − Capex | $-4.9M | $1.6M |
| FCF MarginFCF / Revenue | -53.4% | 17.8% |
| Capex IntensityCapex / Revenue | 1.2% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.8M | $2.0M | ||
| Q3 25 | $-2.6M | $-3.7M | ||
| Q2 25 | $-1.5M | $-5.2M | ||
| Q1 25 | $-3.5M | $-5.1M | ||
| Q4 24 | $-2.3M | $4.0M | ||
| Q3 24 | $-2.5M | $4.1M | ||
| Q2 24 | $-4.8M | $-3.6M | ||
| Q1 24 | $-4.8M | — |
| Q4 25 | $-4.9M | $1.6M | ||
| Q3 25 | $-2.6M | $-4.2M | ||
| Q2 25 | $-1.5M | $-5.7M | ||
| Q1 25 | $-3.5M | $-5.4M | ||
| Q4 24 | $-2.4M | $3.6M | ||
| Q3 24 | $-2.6M | $4.0M | ||
| Q2 24 | $-4.8M | $-3.8M | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | -53.4% | 17.8% | ||
| Q3 25 | -27.3% | -23.7% | ||
| Q2 25 | -16.1% | -36.2% | ||
| Q1 25 | -39.7% | -53.0% | ||
| Q4 24 | -26.3% | 19.6% | ||
| Q3 24 | -30.4% | 22.4% | ||
| Q2 24 | -54.4% | -28.1% | ||
| Q1 24 | -54.2% | — |
| Q4 25 | 1.2% | 4.4% | ||
| Q3 25 | 0.2% | 2.8% | ||
| Q2 25 | 0.4% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.8% | 2.3% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 0.2% | 1.3% | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | -0.78× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
